Ibodutant

Ibodutant was a candidate drug for irritable bowel syndrome diarrhea, developed by The Menarini Group. As of March 2015, it underwent a multicentre double blind efficacy clinical study. Ibodutant selectively blocks the tachykinin receptor NK2, with blockade practically complete in nanomolar concentrations. A phase 2 trial in Europe (the IRIS-2 trial) completed in May 2012 with positive results. A 52-week phase 3 study was terminated as of 2015 because of low response and negative results of study NAK-06.[1]

Ibodutant
Clinical data
Other names6-methyl-N-[1-[[(2R)-1-[[1-(oxan-4-ylmethyl)piperidin-4- yl]methylamino]-1-oxo-3-phenylpropan-2-yl]carbamoyl]cyclopentyl]-1-benzothiophene-2-carboxamide
Routes of
administration		Oral
ATC code
  • none
Identifiers
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
Chemical and physical data
FormulaC37H48N4O4S
Molar mass644.866 g/mol g·mol−1
3D model (JSmol)
 NY (what is this?)  (verify)

See also

References
  1. "Clinical Trials Database". Menarini Group. Retrieved 11 March 2015.
  • H. Spreitzer (May 26, 2008). "Neue Wirkstoffe - Ibodutant". Österreichische Apothekerzeitung (in German) (11/2008): 541.
  • S. Giuliani; M. Altamura; C. A. Maggi. "Ibodutant. Tachykinin NK2 receptor antagonist, Treatment of irritable bowel syndrome". Drugs of the Future. 33 (2): 111–115.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.